GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Other Income (Expense)

Biosyent (TSXV:RX) Other Income (Expense) : C$-26.66 Mil (TTM As of Sep. 2024)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Other Income (Expense)?

Biosyent's other income expense for the Biosyent's pretax income for the three months ended in Sep. 2024 was C$-0.11 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was C$-26.66 Mil.

Biosyent Other Income (Expense) Historical Data

The historical data trend for Biosyent's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Other Income (Expense) Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.91 -12.20 -14.20 -15.78 -18.01

Biosyent Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -17.46 -3.99 -5.10 -0.11

Biosyent Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-26.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosyent  (TSXV:RX) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Biosyent Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Other Income (Expense)
Comparable Companies
XCNQ:AAWH.U XCNQ:VREO XCNQ:AYR.A TSX:HLS XCNQ:JUSH TSXV:SBBC XCNQ:PLTH TSX:CRDL NEOE:CBST XCNQ:IAN ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB VTRS
Traded in Other Exchanges
BIOYF:USA
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Website
http://www.biosyent.com
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Executives
Fax Investments Inc. 10% Security Holder
Peter Douglas Lockhard Director
Seyed Ahmad Ashrafi Director
Sharan Raghubir Senior Officer
Rene Goehrum 10% Security Holder, Director, Senior Officer
Biosyent Inc. Issuer
Fax Capital Corp. 10% Security Holder
Joost Van Der Mark Senior Officer
Robert Joseph March Senior Officer
Sara Elford Director
Alfred D'souza Director

Biosyent Headlines

No Headlines